Drug Trial Radar · NCT05386108
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Aug 2027
Study completion Feb 2029
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.
Conditions
- Breast Neoplasms
- Brain Neoplasms
- Neoplasms by Site
- Neoplasms
- Breast Diseases
- Central Nervous System Neoplasms
- Brain Diseases
- Central Nervous System Diseases
Interventions
ElacestrantDrug
300 mg, 400 mg
AbemaciclibDrug
100 mg, 150 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: RP2DTime frame: Cycle 1 (28 days)
- Phase 2: Objective Response Rate (ORR) Per Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)Time frame: 3 years
Locations
86 sites in 10 countries. Site status is shown where the registry gives one.
Providence Medical Foundation
Fullerton, California · Recruiting
California Research Institute
Los Angeles, California · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Miami Valley Hospital South
Centerville, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Terminated
SCRI Oncology Partners
Nashville, Tennessee · Terminated
University of Texas MD Anderson Cancer Center
Houston, Texas · Terminated
UT Health San Antonio University of Texas
San Antonio, Texas · Terminated
Virginia Cancer Institute
Norfolk, Virginia · Recruiting
Antwerp University Hospital
Edegem, Belgium · Recruiting
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium · Recruiting
Institut de Cancerologie de l'Ouest site Paul Papin
Angers, France · Recruiting
Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie
Brest, France · Recruiting
Centre Francois Baclesse - Oncologie Medicale - Cancerolo
Caen, France · Recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Recruiting
Centre Léon Bérard - Département Oncologie Médicale
Lyon, France · Recruiting
Centre de Cancerologie du Grand Montpellier
Montpellier, France · Recruiting
Hôpital de la Pitiê Salpêtriêre
Paris, France · Recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Klinikum Bayreuth GmbH
Bayreuth, Germany · Recruiting
Uniklinik Koeln - Klinik und Poliklinik fuer Frauenheilkunde
Cologne, Germany · Terminated
Universitatsklinikum Carl Gustav Carus
Dresden, Germany · Recruiting
Universitaetsklinikum Duesseldorf
Düsseldorf, Germany · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Universitätsklinikum Leipzig
Leipzig, Germany · Recruiting
Klinikum Worms gGmbH
Worms, Germany · Recruiting
Helios Klinikum Wuppertal
Wuppertal, Germany · Recruiting
National and Capodistrian University of Athens - University General Hospital Attikon
Athens, Greece · Terminated
Metropolitan Hospital [Oncology]
Piraeus, Greece · Recruiting
EUROMEDICA General Clinic of Thessaloniki
Thessaloniki, Greece · Terminated
Interbalkan European Medical Center
Thessaloniki, Greece · Recruiting
AOU Ospedali Riuniti Umberto I-G.M.Lancisi -G.Salesi
Ancona, Italy · Recruiting
INOC - Istituto Nazionale Oncologico Candiolo
Candiolo, Italy · Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST IRCCS
Meldola, Italy · Recruiting
A. O. Ospedali Riuniti Parpardo, Piemonte, Messina
Messina, Italy · Recruiting
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.